Division of Surgical Research, Department of Surgery, Rhode Island Hospital and the Warren Alpert Medical School of Brown University, Providence, Rhode Island 02903, USA.
J Biol Chem. 2012 Jan 27;287(5):3337-48. doi: 10.1074/jbc.M111.298307. Epub 2011 Dec 9.
Neutrophils provide an innate immune response to tissues infected with fungal pathogens such as Candida albicans. This response is tightly regulated in part through the interaction of integrins with extracellular matrix ligands that are distributed within infected tissues. The β(2) integrin, CR3 (CD11b/CD18), is unique among integrins in containing a lectin-like domain that binds the fungal pathogen-associated molecular pattern β-glucan and serves as the dominant receptor for recognition of fungal pathogens by human granulocytes. β-Glucan, when isolated in soluble form, has been shown to be a safe and effective immune potentiator when administered therapeutically. Currently a pharmaceutical grade preparation of β-glucan is in several clinical trials with an anti-cancer indication. CR3 binding of extracellular matrix, carbohydrate, or both ligands simultaneously differentially regulates neutrophil function through a mechanism not clearly understood. Using FRET reporters, we interrogated the effects of soluble β-glucan on intracellular and extracellular CR3 structure. Although the canonical CR3 ligand fibrinogen induced full activation, β-glucan alone or in conjunction with fibrinogen stabilized an intermediate conformation with moderate headpiece extension and full cytoplasmic tail separation. A set of phosphopeptides differentially regulated by β-glucan in a CR3-dependent manner were identified using functional proteomics and found to be enriched for signaling molecules and proteins involved in transcriptional regulation, mRNA processing, and alternative splicing. These data confirm that CR3 is a signaling pattern recognition receptor for β-glucan and represent the first direct evidence of soluble β-glucan binding and affecting a signaling-competent intermediate CR3 conformation on living cells.
中性粒细胞为组织提供先天免疫反应,以对抗真菌感染病原体,如白色念珠菌。这种反应在一定程度上受到严格调控,部分是通过整合素与分布在感染组织中的细胞外基质配体相互作用实现的。β(2)整合素,CR3(CD11b/CD18),在整合素中是独一无二的,它含有一个凝集素样结构域,可与真菌病原体相关的分子模式β-葡聚糖结合,并作为人类粒细胞识别真菌病原体的主要受体。当以可溶性形式分离的β-葡聚糖进行治疗性给药时,已被证明是一种安全有效的免疫增强剂。目前,一种β-葡聚糖的药物级制剂正在进行几种临床试验,具有抗癌适应症。细胞外基质、碳水化合物或两者配体同时与 CR3 的结合通过一种尚未明确的机制,差异调节中性粒细胞的功能。使用 FRET 报告基因,我们研究了可溶性β-葡聚糖对细胞内和细胞外 CR3 结构的影响。虽然经典的 CR3 配体纤维蛋白原可诱导完全激活,但β-葡聚糖本身或与纤维蛋白原联合可稳定一种中间构象,具有适度的头部延伸和完全的细胞质尾部分离。使用功能蛋白质组学鉴定了一组通过 CR3 依赖性方式被β-葡聚糖差异调节的磷酸肽,并发现它们富含信号分子和参与转录调控、mRNA 加工和选择性剪接的蛋白质。这些数据证实 CR3 是β-葡聚糖的信号模式识别受体,并且代表了第一个关于可溶性β-葡聚糖结合并影响活细胞中信号转导能力的中间 CR3 构象的直接证据。